Skip to content
PeptideTech
Cart

Home / Research library / CagriSema

Blends

CagriSema: molecular data, studies & sources

CagriSema is catalogued here as a combination of ingredients. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

A blend is not one molecule

This is a combination of separate ingredients, not a single molecule. Ingredient molecular weights cannot be added to describe a vial or establish evidence for the blend.

MF: not assigned · MW: not assigned · Structure: not assigned

Catalogued ingredients: Cagrilintide · Semaglutide. The supplier must specify the amount and identity of each ingredient.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list CagriSema as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

29 registered studies matched, 11 currently active or recruiting.

StudyPhase · statusConditionsSponsor · size
Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 DiabetesNCT07817251 · start 2026-09-16 · primary completion 2027-06-09Phase 3RecruitingDiabetes Mellitus, Type 2Novo Nordisk A/S210 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · start 2026-08-04 · primary completion 2029-09-07Phase 3RecruitingDiabetes Mellitus, Type 2Novo Nordisk A/S80 participants
A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 DiabetesNCT07564414 · start 2026-05-21 · primary completion 2028-02-23Phase 3RecruitingObesity · Type 2 DiabetesNovo Nordisk A/S2500 participants
Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and FunctionNCT07527195 · start 2026-04-10 · primary completion 2028-04-28Phase 1RecruitingObesityNovo Nordisk A/S100 participants
Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or ObesityNCT07253285 · start 2026-01-08 · primary completion 2030-03-20Phase 3RecruitingOverweight · ObesityNovo Nordisk A/S460 participants
The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised StudyNCT07184086 · start 2025-09-26 · primary completion 2027-10-12Phase 1Active Not RecruitingObesityNovo Nordisk A/S80 participants
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With ObesityNCT07010432 · start 2025-06-12 · primary completion 2028-05-03Phase 1RecruitingObesityNovo Nordisk A/S144 participants
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With ObesityNCT07011667 · start 2025-06-03 · primary completion 2027-03-01Phase 3Active Not RecruitingObesityNovo Nordisk A/S609 participants
Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With ObesityNCT06780449 · start 2025-02-10 · primary completion 2028-08-28Phase 3Active Not RecruitingObesityNovo Nordisk A/S400 participants
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular DiseaseNCT05669755 · start 2023-03-01 · primary completion 2027-09-01Phase 3Active Not RecruitingCardiovascular DiseaseNovo Nordisk A/S7101 participants
Show 19 more registered studies
StudyPhase · statusConditionsSponsor · size
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or ObesityNCT05567796 · start 2022-11-01 · primary completion 2024-10-30Phase 3Active Not RecruitingObesityNovo Nordisk A/S3400 participants
A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 DiabetesNCT07357740 · start 2026-08-27 · primary completion 2027-08-25Phase 2WithdrawnDiabetes Mellitus, Type 2Novo Nordisk A/SEnrollment not listed
A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or ObesityNCT07357766 · start 2026-06-22 · primary completion 2027-11-29Phase 3WithdrawnOverweight · ObesityNovo Nordisk A/SEnrollment not listed
Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · start 2025-01-29 · primary completion 2026-06-26Phase 2CompletedDiabetes Mellitus, Type 2 · Diabetic Peripheral NeuropathyNovo Nordisk A/S142 participants
Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or ObesityNCT06716307 · start 2024-12-02 · primary completion 2025-03-28Phase 1CompletedObesityNovo Nordisk A/S18 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or BothNCT06534411 · start 2024-11-05 · primary completion 2026-06-02Phase 3CompletedDiabetes Mellitus, Type 2Novo Nordisk A/S1023 participants
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or ObesityNCT06388187 · start 2024-06-24 · primary completion 2026-04-22Phase 3CompletedObesityNovo Nordisk A/S300 participants
Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 · start 2024-05-20 · primary completion 2025-11-21Phase 2CompletedAlcohol-related Liver DiseaseNovo Nordisk A/S270 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or ObesityNCT06131372 · start 2024-04-01 · primary completion 2025-09-24Phase 2CompletedChronic Kidney Disease · Type 2 Diabetes · ObesityNovo Nordisk A/S626 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without MetforminNCT06323161 · start 2024-03-26 · primary completion 2025-09-09Phase 3CompletedType 2 DiabetesNovo Nordisk A/S274 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and ExerciseNCT06323174 · start 2024-03-19 · primary completion 2025-10-01Phase 3CompletedType 2 DiabetesNovo Nordisk A/S189 participants
An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or ObesityNCT06289504 · start 2024-02-27 · primary completion 2024-10-16Phase 1CompletedObesityNovo Nordisk A/S34 participants
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment(CagriSema) on Energy Intake, Appetite and Gastric Emptying in People With Overweight or ObesityNCT06207877 · start 2024-02-23 · primary completion 2024-10-16Phase 1CompletedObesityNovo Nordisk A/S62 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 InhibitorNCT06221969 · start 2024-01-16 · primary completion 2026-03-04Phase 3CompletedType 2 DiabetesNovo Nordisk A/S1024 participants
Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With ObesityNCT06131437 · start 2023-11-27 · primary completion 2025-12-08Phase 3CompletedObesityNovo Nordisk A/S809 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 InhibitorNCT06065540 · start 2023-09-27 · primary completion 2025-11-19Phase 3CompletedType 2 Diabetes MellitusNovo Nordisk A/S2734 participants
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or ObesityNCT05996848 · start 2023-08-15 · primary completion 2025-01-06Phase 3CompletedObesity or OverweightNovo Nordisk A/S300 participants
Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or ObesityNCT05813925 · start 2023-04-03 · primary completion 2025-01-17Phase 3CompletedObesity or OverweightNovo Nordisk A/S331 participants
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 DiabetesNCT05394519 · start 2023-02-01 · primary completion 2025-01-28Phase 3CompletedOverweight · Obesity · Type 2 Diabetes MellitusNovo Nordisk A/S1200 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

No matching human study was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

    Preclinical research, reviews & other publications

    Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

    No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.

      CagriSema supplier sources

      Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

      No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

      Reference sources & further reading

        The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

        Search for additional research

        These links run searches; their results have not been individually reviewed and can include unrelated compounds.

          Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

          Ingredient and related research